Yttrium-90 Ibritumomab Tiuxetan (Zevalin) Followed By BEAM (Z ...

Full text links CiteDisplay options Display options Format AbstractPubMedPMID

Abstract

Chemo-refractory NHL has a very poor outcome; the addiction of RIT to salvage regiment pre ASCT had recently demonstrated promising results.We performed a retrospective sequential study to determine the feasibility of standard Zevalin with BEAM in high-risk relapse/refractory NHL. A matched cohort analysis with a group treated with standard BEAM without Zevalin was performed as secondary endpoint. Between October 2006 and January 2013, 37 NHL patients at high risk for progression or early (< 1 year) or multiple relapses were treated with Z-BEAM and ASCT after R-DHAP or R-ICE as salvage therapy. Clinical characteristics were 19 refractory and 18 early or multiple relapse; 16 patients received 1, and 21 had 2 or more previous rituximab-containing chemotherapy. At the end of treatment, response was CR 22 (59%), PR 10 (27%), PD 4 (11%), and toxic death (TD) 1 (3%). With a median follow up of 61 months, 3-year PFS was 61% and OS 61%. Fifteen patients died, 12 of lymphoma. Comparison with 21 treated with BEAM alone showed a numerical higher 3-yr PFS rate in favor of Z-BEAM but not statistically significant (57 vs 48%). With the limitation of the small sample subgroup analysis, a significant benefit was observed in relapsed patients for PFS (78% Z-BEAM vs 22% BEAM p = 0.016) and OS (83% Z-BEAM vs 22% BEAM p = 0.001). In relapsed/refractory high-risk NHL, Z-BEAM+ASCT is able to achieve a good ORR. Three-year PFS is promising for early relapsed patients but is not satisfactory for those with refractory disease.

Keywords: Aggressive refractory NHL; Autologous stem cell transplantation; Zevalin.

PubMed Disclaimer

Publication types

• Clinical Trial Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search

MeSH terms

• Adolescent Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Adult Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Aged Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Antibodies, Monoclonal / administration & dosage* Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Antineoplastic Combined Chemotherapy Protocols / therapeutic use* Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Carmustine / therapeutic use Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Combined Modality Therapy Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Cytarabine / therapeutic use Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Drug Resistance, Neoplasm / drug effects Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Female Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Hematopoietic Stem Cell Transplantation* Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Humans Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Italy / epidemiology Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Lymphoma, B-Cell / drug therapy Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Lymphoma, B-Cell / epidemiology Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Lymphoma, B-Cell / pathology Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Lymphoma, B-Cell / therapy* Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Lymphoma, Non-Hodgkin / drug therapy Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Lymphoma, Non-Hodgkin / epidemiology Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Lymphoma, Non-Hodgkin / pathology Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Lymphoma, Non-Hodgkin / therapy* Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Male Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Melphalan / therapeutic use Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Middle Aged Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Neoplasm Invasiveness Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Podophyllotoxin / therapeutic use Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Recurrence Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Retrospective Studies Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Salvage Therapy / methods Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Transplantation Conditioning / methods* Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Transplantation, Autologous Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Treatment Outcome Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Young Adult Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Yttrium Radioisotopes / administration & dosage* Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search

Substances

• Antibodies, Monoclonal Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Yttrium Radioisotopes Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Cytarabine Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Yttrium-90 Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• ibritumomab tiuxetan Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Podophyllotoxin Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Melphalan Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Carmustine Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search

Supplementary concepts

• BEAM protocol Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search

LinkOut - more resources

• Full Text Sources

  • Springer

• Other Literature Sources

  • scite Smart Citations

• Research Materials

  • NCI CPTC Antibody Characterization Program